#ACR23 Late-Breaking Abstr#L19 IA steroid can help osteoarthritis knee pain but effect & duration are variable. Phase 3 RCT: improvement in ADP & WOMAC pain favouring TLC5999 (liposomal modification of DEX) vs PBO at all timepoints inc. after repeated injection @RheumNow #ACRBest https://t.co/xUhoFHPExr

Would intraarticular steroids for knee OA be better with a sustained release formulation? ph3, TLL599 (liposomal delivery dexamethasone) vs normal dex vs placebo some gains over normal dex well tolerated New options always welcome in OA! @ProfDavidHunter #ACR23 L19 @RheumNow https://t.co/TUrhppHMiD

L20 #ACR23 @RheumNow Telitacept - Recomb Fusion targets BlyS, APRIL in RA w inadeq MTX response ACR 20 60% v 27% PBO (p<0.001), ACR 50 21% v 6% PBO (p<0.001) DAS28-ESR <3.2 15% v 5%, reduct -1.6 v -1.0 Better PROs, less jt damage prog at w24 Safety SAE 6.4 v 6.7%, no ifn signal https://t.co/PsA6AxUHVW

Sustained relief for knee OA TLC599 - liposomal formulation of dexamethasone sodium phosphate Single injection provided relief for 24 weeks, repeat injection with benefit up to wk 52 @RheumNow #ACR23 Abs#L19 #ACRBest https://t.co/BNGb3nHw8C

#ACR23 Late-Breaking Abstr#L20 Phase 3 RCT in China: Telitacicept (BAFF-APRIL-i) in MTX-IR #RA met ACR20 response vs PBO. +ve: less radiographic damage -ve: lower rate ACR50 (21%), homogenous population, no H2H active comparator Unclear its place in current Mx @RheumNow https://t.co/SAc4B1aRD1

Telitacicept (BlyS/APRIL inhibitor) in MTX-IR RA. Phase 3 RCT. 479 patients. ACR20 60.0% vs 26.9%. ACR50 21.4% vs. 5.9%. Radiographic benefit also. Safety looks ok. Abstr#L20 #ACR23 #ACRbest @RheumNow https://t.co/qcinGeRX2d https://t.co/SIKKW7xhwV

#ACRbest Peter Merkel as Distinguished Investigator said Data are good. Need data to develop questions, understand #vasculitis Hx of #vasculitis - great minds & drugs - now challenged by funding and comparators Session 15W127 #ACR23 @RheumNow @ACRheum https://t.co/5leIeLWZ6O

Tommasi et al. MTX (vs SSZ) lowers BP in RA in RCT. At 6 months, significant reduction in SBP (mean difference -4.0±10.8 mmHg, p=0.038), MAP (mean difference -4.3±17.9 mmHg, p=0.023). Abstr#2151 #ACR23 @RheumNow https://t.co/wAX3dCztxH https://t.co/mPG5TdeHTu

#vasculitis clinical trials are accelerating. Need the right time - early studies have lessons learned re feasibility and design/endpoints #ACR23 @RheumNow @ACRheum Great lecture - P Merkel 15W127 great graphs of vasculitis developments https://t.co/YRdPiaflxY

Knee OA, to inject or not to inject: the great debate 📣 A thread👇🏼👇🏼👇🏼 Maglette Klotenburg argues in favor, with moderation IA GC improves pain Repetitive injections can be harmful @RheumNow #ACR23 https://t.co/3p4UVLngpx